Amgen (AMGN) reported second-quarter 2026 total revenues of $10.1 billion, up 10% from the prior-year period. GAAP earnings per share rose 65% to $4.37, while GAAP operating income increased to $3.5 billion and GAAP operating margin rose to 36.8%.
The company said product sales grew 9%, driven by volume growth, with 22 products delivering at least double-digit sales growth in the quarter. Amgen also generated $3.5 billion of free cash flow and ended June 30, 2026, with $14.0 billion in cash and cash equivalents.
- Total product sales were $9.537 billion, including $6.990 billion in the U.S. and $2.547 billion outside the U.S.
- Repatha sales increased 37% year over year to $953 million, and EVENITY sales rose 38% to $714 million.
- Prolia sales declined 32% to $759 million, while XGEVA sales fell 34% to $352 million.
- Amgen declared a second-quarter dividend of $2.52 per share, paid June 5, 2026, up 6% from the same period in 2025.
- For 2026, Amgen expects total revenues of $38.2 billion to $39.4 billion and GAAP EPS of $15.80 to $17.08.
$AMGN Insider Trading Activity
$AMGN insiders have traded $AMGN stock on the open market 4 times in the past 6 months. Of those trades, 0 have been purchases and 4 have been sales.
Here’s a breakdown of recent trading of $AMGN stock by insiders over the last 6 months:
- ESTEBAN SANTOS (EVP, Operations) has made 0 purchases and 2 sales selling 54,792 shares for an estimated $20,772,595.
- NANCY A. GRYGIEL (SVP & CCO) sold 1,237 shares for an estimated $400,450
- MATTHEW C. BUSCH (VP, Finance & CAO) sold 1,000 shares for an estimated $375,790
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$AMGN Hedge Fund Activity
We have seen 1,323 institutional investors add shares of $AMGN stock to their portfolio, and 1,342 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CAPITAL INTERNATIONAL INVESTORS removed 11,063,995 shares (-60.8%) from their portfolio in Q1 2026, for an estimated $3,892,866,640
- CAPITAL WORLD INVESTORS added 6,190,632 shares (+26.8%) to their portfolio in Q1 2026, for an estimated $2,178,173,869
- CAPITAL RESEARCH GLOBAL INVESTORS added 2,307,190 shares (+49.6%) to their portfolio in Q1 2026, for an estimated $811,784,801
- ROCKEFELLER CAPITAL MANAGEMENT L.P. removed 1,645,235 shares (-71.9%) from their portfolio in Q1 2026, for an estimated $578,875,934
- GEODE CAPITAL MANAGEMENT, LLC added 1,127,230 shares (+7.9%) to their portfolio in Q1 2026, for an estimated $396,615,875
- CHARLES SCHWAB INVESTMENT MANAGEMENT INC added 962,341 shares (+8.1%) to their portfolio in Q1 2026, for an estimated $338,599,680
- UBS GROUP AG removed 956,484 shares (-23.3%) from their portfolio in Q1 2026, for an estimated $336,538,895
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$AMGN Congressional Stock Trading
Members of Congress have traded $AMGN stock 5 times in the past 6 months. Of those trades, 2 have been purchases and 3 have been sales.
Here’s a breakdown of recent trading of $AMGN stock by members of Congress over the last 6 months:
- REPRESENTATIVE DAVID TAYLOR has traded it 2 times. They made 1 purchase worth up to $15,000 on 06/05 and 1 sale worth up to $15,000 on 02/26.
- REPRESENTATIVE MARIA ELVIRA SALAZAR has traded it 2 times. They made 1 purchase worth up to $50,000 on 03/24 and 1 sale worth up to $50,000 on 04/17.
- SENATOR ALAN ARMSTRONG sold up to $50,000 on 03/27.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.
